Data sources The Medline, Embase and CINAHL databases were used to source studies, along with the reference lists of identified articles. Study selection Studies were restricted to randomised controlled trials (RCT), written in English, where the outcome of mucositis was recorded using the World Health Organization score or the NCI-CTC (National Cancer Institute-Common Toxicity Criteria) score, the absence or presence of ulcerations, or the presence or absence of grades 3 and 4 mucositis. Data extraction and synthesis A total of 45 studies was included in a meta-analysis. When the included studies showed heterogeneity regarding the effect estimates, the results of the meta-analyses were based on the random-effects models; otherwise, the results were based on the fixed-effects models.
Results The search yielded 109 publications, 45 articles being included in the meta-analyses. These evaluated eight different interventions: local application of chlorhexidine; iseganan; PTA (polymyxin E, tobramycine and amphotericin B); granulocyte macrophage-colony-stimulating factor/ granulocyte colony-stimulating factor (GM-CSF/ G-CSF); oral cooling; sucralfate and glutamine; and systemic administration of amifostine and GM-CSF/G-CSF. Four interventions showed a significant preventive effect on the development or severity of oral mucositis: PTA [odds ratio (OR), 0.61; 95% confidence interval (CI), 0.39-0.96]; GM-CSF (OR, 0.53; 95% CI, 0.33-0.87); oral cooling (OR, 0.3; 95% CI, and amifostine (OR, 0.37; 95% CI, ).
Conclusions From current data, it can be concluded that no single intervention is capable of completely preventing oral mucositis. Future studies should evaluate a combination of interventions for the prevention of oral mucositis. In contrast, novel therapies could be developed that will improve outcomes and be used as single agents.
Commentary
Oral mucositis is a significant problem for patients undergoing treatment for cancer in general, and for head and neck cancers in particular. A systematic review by Trotti et al. 1 noted that mucositis is a frequent and severe consequence of radiotherapy, occurring in the majority of patients being treated for head and neck cancer; the mean incidence is 80%.
There have been a number of reviews of this area, of the traditional narrative type and also more systematic ones -most notably two Cochrane reviews looking at the prevention and treatment of oral mucositis in people receiving treatment for cancer. The recently updated Cochrane review on the prevention of oral mucositis is sum-
